慣性聚合 高效追讀感興趣之博客、新聞、科技資訊
閱原文 以慣性聚合開啟

推薦訂閱源

小众软件
小众软件
博客园 - 叶小钗
有赞技术团队
有赞技术团队
大猫的无限游戏
大猫的无限游戏
博客园_首页
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
L
LangChain Blog
Hugging Face - Blog
Hugging Face - Blog
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
aimingoo的专栏
aimingoo的专栏
Blog — PlanetScale
Blog — PlanetScale
爱范儿
爱范儿
T
Tailwind CSS Blog
Jina AI
Jina AI
量子位
Stack Overflow Blog
Stack Overflow Blog
人人都是产品经理
人人都是产品经理
J
Java Code Geeks
V
Visual Studio Blog
月光博客
月光博客

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem CuriosityStream: AI Is Not Enough For An Investment Here Akamai Collapse: Did Anthropic Just Kill Its Prospects? I Think Not Potential $5,000 Monthly Income - 12 Investments To Buy And Hold For The Next 10 Years Citizens Financial Group: Q1 Results Should Validate Recent Strength Weekly Indicators: The Consumer Continues To Spend Like There's No Tomorrow Don't Overlook Arthur J. Gallagher & Co. When Investing Global Ship Lease: Embedded Upside From Charter Repricing And Trade Disruption Marvell: Rating Upgrade On Data Center Boom EMCOR Group: Solid Business That Is Fully Valued High-Yield REITs I Would Trust For Retirement Income Rubrik's Growth Engines Are Working, But 18% Dilution Risk Weighs On The Upside Coeur Mining: The Market Is Still Pricing The Old CDE Morgan Stanley Direct Lending Has Some Issues, But The Price Makes It Buyable Exploring Digital Equity With These 3 Stocks Twin Disc's Pop Means It's Time For A Downgrade Peloton: Great Improvements But With An Idea Lacking Evidence Tap The Brakes And Buy SPLV Clean Up Your Portfolio With Bath & Body Works Devon-Coterra Merger: Good And Bad Tyson Foods: Pivoting Beyond Cyclicality Into Structural Growth
汉莎生物制药公司AB(上市)(HNSBF)讨论Imlifidase在高度敏感肾移植患者中PAES研究之要旨实录
2026-05-28 · via All Articles on Seeking Alpha

汉莎生物制药股份公司(Hansa Biopharma AB (publ))(HNSBF)论及Imlifidase于高度敏感肾移植患者之PAES研究要旨,时在2026年5月27日,午前八时(东部夏令时)

与会者

雷内·阿吉亚尔-卢卡德 - 首席执行官
理查德·菲利普森 - 首席医疗官

电话会议与会者

布莱恩·康利 - Leerink Partners LLC,研究部
马修·菲普斯 - William Blair&公司L.L.C.,研究部
苏珊·范·沃瑟胡森 - Kempen&公司N.V.,研究部

演讲

操作者

吉时辰,欢迎至汉莎生物制药会议。[操作须知]请注意,此活动正被录制。今将会议交予汉莎生物制药之CEO,雷内·阿吉亚尔-卢卡德。请其发言。

雷内·阿吉亚尔-卢卡德
首席执行官

谢忱至矣。午安或晨安。谨邀诸君参与Hansa Biopharma之会议,以呈报PAES研究之要旨。此诚吾辈公司之盛日,亦信为今日众多高度敏感之患者,除透析外别无他选之吉日。吾辈甚感荣幸,得与诸君分享吾辈授权后之疗效研究之佳果。吾乃Hansa Biopharma之CEO Renee Aguiar-Lucander。今日与吾同席者,乃Richard Philipson,任首席医学官。

请翻至下一页。容吾示君,吾等将于演讲中作前瞻之语。尔宜慎之。

请翻至下一页。今日之议程甚简。吾初为引言,继而吾之CMO将呈报要旨,吾等复将略述后续之步。在Q... &一席话

请翻至下一页。若诸君未谙汉莎生物制药,吾辈有创制之 IgG 裂解平台,此实专注酵素也。